PDP

Epsilon Reports First Quarter 2024 Results

Retrieved on: 
Mercredi, mai 8, 2024
Permian, NRI, Central Time, Investment, News, Natural gas, TILS, MMBTU, Conference, Webcast, PDP, TIL, Acquisition, Interest, Cubic foot, Oil

Epsilon’s capital expenditures were $21.4 million for the quarter ended March 31, 2024.

Key Points: 
  • Epsilon’s capital expenditures were $21.4 million for the quarter ended March 31, 2024.
  • In addition, our operating partner in PA curtailed production in response to low realized gas prices in the first quarter (quantified above).
  • The Company will host a conference call to discuss its results on Thursday, May 9, 2024 at 9:30 a.m. Central Time (10:30 a.m. Eastern Time).
  • Participants should ask to be joined to the “Epsilon Energy First Quarter 2024 Earnings Conference Call.”
    A webcast can be viewed at: https://event.choruscall.com/mediaframe/webcast.html?webcastid=BtayVC7k .

Turtle Beach Announces First Quarter 2024 Earnings Results

Retrieved on: 
Mardi, mai 7, 2024
Hardware, Electronic Games, Consumer Electronics, Technology, Entertainment, CFO, Rationalization, Depreciation, Turtle Beach Corporation, Security (finance), Inventory, Webcast, PDP, Tax, SKU, Acquisition, Adjustment, GAAP, Growth, Bookkeeping

Turtle Beach Corporation (Nasdaq: HEAR) (“Turtle Beach” or the “Company”), a leading gaming accessories brand, today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Turtle Beach Corporation (Nasdaq: HEAR) (“Turtle Beach” or the “Company”), a leading gaming accessories brand, today reported financial results for the first quarter ended March 31, 2024.
  • “Our first quarter results were in-line with our expectations and track well to our full year 2024 plan,” said Cris Keirn, Chief Executive Officer, Turtle Beach Corporation.
  • Operating expenses in the first quarter of 2024 were $23.5 million compared to $20.6 million a year ago, including $5.0 million in acquisition-related costs.
  • The weighted average diluted share count for the first quarter of 2024 was 19.4 million compared to 16.6 million in the year-ago quarter.

Sovos Introduces Indirect Tax Suite to Meet Complexities of Global Compliance

Retrieved on: 
Mardi, avril 30, 2024
Software, Networks, Accounting, Internet, Professional Services, Business, Fintech, Data Management, Apps, Applications, Technology, Data Analytics, Finance, Cloud, Organization, SUT, Risk, PEPPOL, ERP, GST, B2C, VAT, PDP, Chinese, Use tax, File, Intelligence, Consumption tax, Government, Indirect tax, Sales

Sovos , the always-on compliance company, introduces its Indirect Tax Suite, a comprehensive, integrated solution to modernize how companies meet global indirect tax obligations.

Key Points: 
  • Sovos , the always-on compliance company, introduces its Indirect Tax Suite, a comprehensive, integrated solution to modernize how companies meet global indirect tax obligations.
  • Part of the Sovos Compliance Cloud , the Indirect Tax Suite empowers enterprises to manage all of their indirect tax obligations with governments, buyers, suppliers and consumers.
  • “With the Sovos Indirect Tax Suite, companies can rely on the only comprehensive, global, always-on suite of integrated services in the industry to proactively manage compliance, benefiting from a single source of truth for tax data,” continued Akeroyd.
  • Global Determination: Sovos’ Global Tax Determination engine provides automated, accurate tax rates and rule updates for Sales and Use Tax (SUT), Value Added Tax (VAT) and Goods and Services Tax (GST) in 195 countries.

50%+ of Medicare Eligibles Selected a Medicare Advantage Plan in 2024 per Mark Farrah Associates’ Report

Retrieved on: 
Lundi, avril 29, 2024
Insurance, Finance, Banking, Professional Services, Public Policy, Government, Healthcare Reform, General Health, Data Analytics, Pharmaceutical, Health, CVS, Humana, Cigna, PDP, MFA, UnitedHealth Group, Medicare, Health insurance

Mark Farrah Associates (MFA), www.markfarrah.com , recently assessed Medicare Advantage (MA), including Medicare Advantage with Prescription Drug Plan (MA-PD) and Prescription Drug Plan (PDP) performance, market share and market growth by state as of April 1, 2024.

Key Points: 
  • Mark Farrah Associates (MFA), www.markfarrah.com , recently assessed Medicare Advantage (MA), including Medicare Advantage with Prescription Drug Plan (MA-PD) and Prescription Drug Plan (PDP) performance, market share and market growth by state as of April 1, 2024.
  • Report findings indicate more than half of people eligible for Medicare selected a Medicare Advantage plan and another third selected a Part D - prescription drug plan in 2024.
  • Total MA membership exceeded 33.4 million and Medicare stand-alone PDPs covered nearly 22.7 million members.
  • Many companies conduct their post-OEP (Open Enrollment Period) competitive assessments by using tools such as Mark Farrah Associates’ (MFA) Medicare Business Online™, Medicare Benefits Analyzer™, and Health Coverage Portal™.

EBP Shareholders Enter into Exclusive Negotiations with Cegid to Create a European Leader in the Highly Strategic and Growing Market for Micro and SMB Enterprise Software

Retrieved on: 
Mercredi, avril 24, 2024
Software, Networks, Human Resources, Data Management, Small Business, Accounting, Professional Services, Technology, Small business, Investment, Treasury, SMB, ERP, Entrepreneurship, Partnership, Artificial intelligence, PDP, Software as a service, Intelligence, Culture, Leclercq, Acquisition, Luigi, EBP, Silver, Growth, Retail

With its existing footprint in Iberia and Belgium, this opportunity also allows Cegid to strengthen its European leadership with this new position in the French market.

Key Points: 
  • With its existing footprint in Iberia and Belgium, this opportunity also allows Cegid to strengthen its European leadership with this new position in the French market.
  • “With the acquisition of EBP, we are accelerating our European strategy in serving small businesses, one of Cegid’s five priority markets.
  • By combining our two companies, EBP and Cegid, we become a leader with annual revenue close to one billion euros and serving close to 750,000 customers.
  • With Cegid, we are proud to embark on this exciting journey to better serve our clients and conquer new markets together,” concludes René Sentis, Founder & CEO of EBP.

PDP Celebrates Fortnite Festival Season 3 With the Launch of the RIFFMASTER Wireless Guitar Controller

Retrieved on: 
Mardi, avril 23, 2024
Generation Z, Retail, Teens, Men, TV and Radio, Online Retail, Electronic Games, Consumer, Department Stores, Consumer Electronics, Technology, Entertainment, Public Relations, Investor Relations, Millennials, Online, Mobile Entertainment, Communications, General Entertainment, PS5, Launch, Rock Band, MSRP, Rock Band 4, News, Performance, Xbox, Turtle Beach Corporation, PDP, Amazon, Product management, PlayStation, Xbox One, Multimedia, PS4, Video game

Leading gaming accessory maker Turtle Beach Corporation (Nasdaq: HEAR), and Performance Designed Products LLC (PDP) today announced the official launch of PDP’s highly-coveted RIFFMASTER wireless guitar controller ($129.99 MSRP).

Key Points: 
  • Leading gaming accessory maker Turtle Beach Corporation (Nasdaq: HEAR), and Performance Designed Products LLC (PDP) today announced the official launch of PDP’s highly-coveted RIFFMASTER wireless guitar controller ($129.99 MSRP).
  • The RIFFMASTER is the first guitar controller designed for today’s rhythm-action gamers and is compatible with Fortnite Festival Pro Lead and Pro Bass song parts in addition to Rock Band™ 4.
  • View the full release here: https://www.businesswire.com/news/home/20240423402701/en/
    PDP Celebrates Fortnite Festival Season 3 with the Launch of the Riffmaster Wireless Guitar Controller (Graphic: Business Wire)
    Pre-orders for the RIFFMASTER sold out just hours following its debut last month.
  • Fans that pre-ordered their RIFFMASTER early are receiving their controllers now during this initial wave of its rolling launch.

Mark Farrah Associates Presents Medicare Plan Benefits in Medicare Benefits Analyzer™

Retrieved on: 
Lundi, avril 22, 2024
Banking, Professional Services, Other Health, Health, General Health, Seniors, Pharmaceutical, Health Insurance, Insurance, Consumer, Finance, Table, CMS, PDP, MFA, PCP, Associate, Medicare, MBA, Health insurance

Mark Farrah Associates (MFA), www.markfarrah.com simplifies analysis of Medicare benefits and Star Quality Ratings information in Medicare Benefits Analyzer™ (MBA).

Key Points: 
  • Mark Farrah Associates (MFA), www.markfarrah.com simplifies analysis of Medicare benefits and Star Quality Ratings information in Medicare Benefits Analyzer™ (MBA).
  • This powerful web-based application presents the latest plan premiums, PCP and specialist co-pays, prescription drug tier pricing, co-pays for inpatient and outpatient procedures, specialty benefits and many additional data elements in a comparative database format.
  • Subscribers to Medicare Benefits Analyzer™ use interactive tables and the File Export Library to download MA and PDP benefits data to assess which plans have competitive selling advantages, county by county.
  • For more information about Medicare Benefits Analyzer™, visit the product page on the Mark Farrah Associates website .

Mark Farrah Associates Presents Health Insurance Market Share at the County Level

Retrieved on: 
Mardi, avril 16, 2024
Insurance, Managed Care, Finance, General Health, Health, Professional Services, Health Insurance, Other Health, Intelligence, HMO, Private, MFA, PPO, Medicaid, Medicare Advantage, PDP, Medicare, Metropolitan statistical area

Mark Farrah Associates, www.markfarrah.com , a leading provider of market data and intelligence solutions, provides county-level market share and demographics data essential for the analysis of health insurance market position and competition.

Key Points: 
  • Mark Farrah Associates, www.markfarrah.com , a leading provider of market data and intelligence solutions, provides county-level market share and demographics data essential for the analysis of health insurance market position and competition.
  • MFA maintains reasonable estimates of health plan membership by county in the County Health Coverage™ product.
  • This product features company market share by state, county, and plan for the Private Risk; now with Individual and Group segments split out, Private ASO, Managed Medicaid, Medicare Advantage, and PDP segments.
  • are also presented, as well as market share by Metropolitan Statistical Areas (MSAs), population demographics and visual mapping tools.

CALC Announces 2023 Annual Results

Retrieved on: 
Mardi, mars 19, 2024
Aircraft, TransNusa, CALC, Moody's Investors Service, Growth, RMB, Airbus, ESG, ARJ21, PDP, CAG, BA1, COMAC, USD, Economics, Fitch, AAA, Airline

Shareholders Profit Surged by Four Times

Key Points: 
  • Shareholders Profit Surged by Four Times
    HONG KONG, Mar 19, 2024 - (ACN Newswire) - China Aircraft Leasing Group Holdings Limited ("CALC" or the "Company", together with its subsidiaries, the "Group"; SEHK stock code: 01848), a full value chain aircraft solutions provider for the global aviation industry, is pleased to announce its annual results for the year ended 31 December 2023 (the "Review Year").
  • Together with the 2023 interim dividend of HK$0.15 per share already paid, total dividend payout for the year 2023 amounted to HK$0.30 (2022: HK$0.30 per share).
  • The Company has resumed its scrip dividend scheme for the final dividend for 2023.
  • As at 31 December 2023, the Group had cash and cash equivalents amounting to HK$5,300 million up 49.1% year-on-year.

TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned

Retrieved on: 
Mercredi, avril 3, 2024
Sarcoma, TCON, Patient, SAN, PDP, Safety, UPS, MFS, Therapy, IDMC, Medical imaging

SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent Product Development Platform (PDP) to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced the independent data monitoring committee (IDMC), following a review of ongoing safety and efficacy data on April 2, recommended the ENVASARC Phase 2 pivotal trial continue as planned. The ENVASARC Phase 2 pivotal trial completed enrollment in March 2024 with a total of 82 evaluable patients in cohort C of treatment with single agent envafolimab at 600 mg SQ every three weeks and final data are expected in the third quarter of 2024.

Key Points: 
  • The ENVASARC Phase 2 pivotal trial completed enrollment in March 2024 with a total of 82 evaluable patients in cohort C of treatment with single agent envafolimab at 600 mg SQ every three weeks and final data are expected in the third quarter of 2024.
  • The IDMC reviewed interim safety and efficacy data from 73 patients enrolled into cohort C who had the opportunity to complete two on-treatment scans (a minimum of 12 weeks of treatment).
  • The objective response rate (ORR) is currently 11% by investigator review and the confirmed ORR by blinded independent central review (BICR) is currently 5.5% (four patients).
  • Envafolimab has been well tolerated without the development of a single drug-related serious adverse event of grade 3 or higher.